MedTrace Logo

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

NCT00406900 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 560

Last updated 2006-12-06

No results posted yet for this study

Summary

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Conditions

Interventions

PROCEDURE

Treatment of metastatic disease

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Ulrich C Schaller, MD · University of Munich, Germany

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Completion
2006-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406900 on ClinicalTrials.gov